The erythrocyte stimulating hormone erythropoetin (Recormon®) is an endogenous hormone identical active substance, which is in successful use for medication of anaemia from dialysis patient. The thrombolytical reteplase (Rapilysin®) is an recombinant produced pharmaceutical of the second generation, which optimises the medication of cardiac infarct. These proteins for human therapy are produced in two highly sophisticated bioprocess plants. These production systems are designed to produce high amounts of biologically active substances. Using state-of-the-art production concepts, these plants were designed and built for efficiency. Special consideration was given to each process step in order to achieve self-contained, highly automated, recipe-based systems. The equipment and process flow at the Penzberg facility incorporate the most current of cGMP principles. The plants were delivered turn-key by BBI . The following individual tasks have been performed:

  Detailed design for process equipment and transfer systems
  Manufacturing of all fermenters and process vessels
  Installation and piping on site
  Integration of package units from other vendors (high pressure    homogenizer, separator)
  Design and Installation of field instrumentation, using fieldbus technology
  Specification, programming and test of control software (phase logic) and    HMI Software for PLC and SCADA systems
  Installation of the control system and performance of qualification tests    (IQ/OQ)